Drugs & Targets FDA approves Anktiva for non-muscle-invasive bladder cancer April 26, 2024Vol.50 No.17
Drugs & Targets Health Canada approves Keytruda for gastroesophageal cancer April 26, 2024Vol.50 No.17
Drugs & Targets European Commission approves Xtandi for high-risk BCR nmHSPC April 26, 2024Vol.50 No.17
Drugs & Targets CHMP recommends approval of Opdivo combination for urothelial carcinoma April 26, 2024Vol.50 No.17
Drugs & Targets FDA revises industry guidance on biologics promotion and advertising April 26, 2024Vol.50 No.17
Drugs & Targets FDA approves Alecensa for ALK-positive early-stage lung cancer April 19, 2024Vol.50 No.16
Drugs & Targets MD Anderson and CureVac collaborate to develop mRNA cancer vaccines April 19, 2024Vol.50 No.16
Drugs & Targets COTA and Sanofi collaborate to accelerate cancer trials using real-world data and AI April 19, 2024Vol.50 No.16
Drugs & Targets FDA grants accelerated approval to Enhertu for unresectable or metastatic HER2-positive solid tumors April 12, 2024Vol.50 No.15
